BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16320199)

  • 1. Hyperforin acts as an angiogenesis inhibitor.
    Schempp CM; Kiss J; Kirkin V; Averbeck M; Simon-Haarhaus B; Kremer B; Termeer CC; Sleeman J; Simon JC
    Planta Med; 2005 Nov; 71(11):999-1004. PubMed ID: 16320199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Examination of different factors influencing the vascularization of human cutaneous melanoma].
    Kiss J
    Magy Onkol; 2008 Dec; 52(4):385-9. PubMed ID: 19068467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo.
    Rothley M; Schmid A; Thiele W; Schacht V; Plaumann D; Gartner M; Yektaoglu A; Bruyère F; Noël A; Giannis A; Sleeman JP
    Int J Cancer; 2009 Jul; 125(1):34-42. PubMed ID: 19326439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperforin, a bio-active compound of St. John's Wort, is a new inhibitor of angiogenesis targeting several key steps of the process.
    Martínez-Poveda B; Quesada AR; Medina MA
    Int J Cancer; 2005 Dec; 117(5):775-80. PubMed ID: 15981212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperforin: more than an antidepressant bioactive compound?
    Medina MA; Martínez-Poveda B; Amores-Sánchez MI; Quesada AR
    Life Sci; 2006 Jun; 79(2):105-11. PubMed ID: 16438991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent.
    Lorusso G; Vannini N; Sogno I; Generoso L; Garbisa S; Noonan DM; Albini A
    Eur J Cancer; 2009 May; 45(8):1474-84. PubMed ID: 19223175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis.
    Schempp CM; Kirkin V; Simon-Haarhaus B; Kersten A; Kiss J; Termeer CC; Gilb B; Kaufmann T; Borner C; Sleeman JP; Simon JC
    Oncogene; 2002 Feb; 21(8):1242-50. PubMed ID: 11850844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic insights into the antileukemic activity of hyperforin.
    Billard C; Merhi F; Bauvois B
    Curr Cancer Drug Targets; 2013 Jan; 13(1):1-10. PubMed ID: 22924417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetrahydrohyperforin and octahydrohyperforin are two new potent inhibitors of angiogenesis.
    Martínez-Poveda B; Verotta L; Bombardelli E; Quesada AR; Medina MA
    PLoS One; 2010 Mar; 5(3):e9558. PubMed ID: 20224821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperforin.
    Beerhues L
    Phytochemistry; 2006 Oct; 67(20):2201-7. PubMed ID: 16973193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperforin Inhibits Cell Growth by Inducing Intrinsic and Extrinsic Apoptotic Pathways in Hepatocellular Carcinoma Cells.
    Chiang IT; Chen WT; Tseng CW; Chen YC; Kuo YC; Chen BJ; Weng MC; Lin HJ; Wang WS
    Anticancer Res; 2017 Jan; 37(1):161-167. PubMed ID: 28011486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer agent.
    Gartner M; Müller T; Simon JC; Giannis A; Sleeman JP
    Chembiochem; 2005 Jan; 6(1):171-7. PubMed ID: 15593112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperforin inhibits MMP-9 secretion by B-CLL cells and microtubule formation by endothelial cells.
    Quiney C; Billard C; Mirshahi P; Fourneron JD; Kolb JP
    Leukemia; 2006 Apr; 20(4):583-9. PubMed ID: 16467866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo.
    Feisst C; Pergola C; Rakonjac M; Rossi A; Koeberle A; Dodt G; Hoffmann M; Hoernig C; Fischer L; Steinhilber D; Franke L; Schneider G; Rådmark O; Sautebin L; Werz O
    Cell Mol Life Sci; 2009 Aug; 66(16):2759-71. PubMed ID: 19579006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperforin depletes synaptic vesicles content and induces compartmental redistribution of nerve ending monoamines.
    Roz N; Rehavi M
    Life Sci; 2004 Oct; 75(23):2841-50. PubMed ID: 15464835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures.
    Komoroski BJ; Zhang S; Cai H; Hutzler JM; Frye R; Tracy TS; Strom SC; Lehmann T; Ang CY; Cui YY; Venkataramanan R
    Drug Metab Dispos; 2004 May; 32(5):512-8. PubMed ID: 15100173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperforin, a new lead compound against the progression of cancer and leukemia?
    Quiney C; Billard C; Salanoubat C; Fourneron JD; Kolb JP
    Leukemia; 2006 Sep; 20(9):1519-25. PubMed ID: 16791262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
    Tian R; Koyabu N; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
    Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits.
    Dinamarca MC; Cerpa W; Garrido J; Hancke JL; Inestrosa NC
    Mol Psychiatry; 2006 Nov; 11(11):1032-48. PubMed ID: 16880827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperforin induces apoptosis through extrinsic/intrinsic pathways and inhibits EGFR/ERK/NF-κB-mediated anti-apoptotic potential in glioblastoma.
    Hsu FT; Chen WT; Wu CT; Chung JG
    Environ Toxicol; 2020 Oct; 35(10):1058-1069. PubMed ID: 32485087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.